Hendrik Paul Van Poppel

Prof. Dr. Hendrik Paul Van Poppel

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
Tit AlbrehtTit Albreht
Tit Albreht
PBPartha Basu
Partha Basu
RHRenée Hogenhout
Renée Hogenhout
SCSarah Collen
Sarah Collen
Monique RoobolMonique Roobol
Monique Roobol

1 December 2021 in European Urology
Verified
Journal Article
Closed access
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
MRMonique J. Roobol
Monique J. Roobol
CCChristopher R. Chapple
Christopher R. Chapple
JCJames W.F. Catto
James W.F. Catto
JNJames N’dOw
James N’dOw
MWManfred Wirth
Manfred Wirth

1 October 2008 in European Urology
Verified
Journal Article
Closed access
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
BTBertrand TOMBAL
Bertrand TOMBAL
JRJean J. de la Rosette
Jean J. de la Rosette
BPBo-Eric Persson
Bo-Eric Persson
JJJens-Kristian Jensen
Jens-Kristian Jensen
TOTine Kold Olesen
Tine Kold Olesen

1 October 2021 in European Urology Oncology
Verified
Journal Article
Open access
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
RHRenée Hogenhout
Renée Hogenhout
PAPeter Albers
Peter Albers
RBRoderick C.N. van Den Bergh
Roderick C.N. van Den Bergh
JBJelle O. Barentsz
Jelle O. Barentsz
MRMonique J. Roobol
Monique J. Roobol
Overdiagnosis as the argument to stop prostate cancer (PCa) screening is less valid since the introduction of new technologies such as risk calculators (RCs) and magnetic resonance imaging (MRI). These new technologies result in fewer unnecessary biopsy procedures and fewer cases of both overdiagnosis and underdetection. Therefore, we can now adequately respond to the growing and urgent need for a structured risk assessment to detect PCa early. To provide expert discussion on the existing evidence for a previously published risk-stratified strategy regarding an organised population-based early detection programme for PCa. The proposed algorithm for early detection of PCa emerged from expert consensus by the authors based on available evidence derived from a nonsystematic review of the current literature using Medline/PubMed, Cochrane Library database, ClinicalTrials.gov, ISRCTN Registry, and the European Association of Urology guidelines on PCa. Although not confirmed by the highest level of evidence, current literature and guidelines point towards an algorithm for early detection of PCa that starts with risk-based prostate-specific antigen (PSA) testing, followed by multivariable risk stratification with RCs. All men who are classified to be at intermediate and high risk are then offered prostate MRI. The combined data from RCs and MRI results can be used to select men for prostate biopsy. Low-risk men return to a risk-based safety net that includes individualised PSA-interval tests and, if necessary, repeated MRI. Depending on local availability, the use of the different risk stratification tools may be adapted. We present a risk-stratified algorithm for an organised population-based early detection programme for clinically significant PCa. Although the proposed strategy has not yet been analysed prospectively, it exploits and may even improve the most important available benefits of "PSA-only" screening studies, while at the same time reduces unnecessary biopsies and overdiagnosis by using new risk stratification tools. This paper presents a personalised strategy that enables selective early detection of prostate cancer by combining prostate-specific antigen (interval) testing' prediction models (risk calculators), and magnetic resonance imaging scans. This will likely lead to reduced prostate cancer-related morbidity and mortality, while reducing the need for prostate biopsy and limiting overdiagnosis.

15 September 2021 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
GDGaëtan Devos
Gaëtan Devos
Wout DevliesWout Devlies
Wout Devlies
GMGert De Meerleer
Gert De Meerleer
MBMarcella Baldewijns
Marcella Baldewijns
TGThomas Gevaert
Thomas Gevaert
Steven JoniauSteven Joniau
Steven Joniau

1 March 2021 in European Urology
Verified
Journal Article
Closed access
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
RHRenée Hogenhout
Renée Hogenhout
PAPeter Albers
Peter Albers
RBRoderick C.N. van Den Bergh
Roderick C.N. van Den Bergh
JBJelle O. Barentsz
Jelle O. Barentsz
MRMonique J. Roobol
Monique J. Roobol